Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 6/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.37 |
| ▸ | METAP1 | P53582 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | APLNR | P35414 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30271368 | 0.86 | GAA (0.44) | AAK1GAAP2RX3SMN1; SMN2POLB | |
| SCHEMBL24195947 | 0.81 | AAK1 (0.41) | AAK1P2RX3METAP1APLNRCYP17A1 | |
| SCHEMBL30755736 | 0.79 | P2RX3 (0.42) | AAK1GAAP2RX3SMN1; SMN2APLNR | |
| SCHEMBL32667285 | 0.76 | AAK1 (0.40) | AAK1GAAP2RX3SMN1; SMN2APLNR | |
| SCHEMBL17553623 | 0.75 | SMN1; SMN2 (0.46) | GAASMN1; SMN2POLBMEN1LMNA | |
| SCHEMBL30778501 | 0.74 | P2RX3 (0.44) | AAK1P2RX3POLBLMNARXFP1 | |
| SCHEMBL26633347 | 0.73 | GSK3B (0.42) | AAK1P2RX3APLNRMAPK1ALK | |
| SCHEMBL30271346 | 0.73 | CYP17A1 (0.37) | AAK1GAAMETAP1SMN1; SMN2POLB | |
| SCHEMBL21046797 | 0.72 | GAA (0.41) | AAK1GAAP2RX3SMN1; SMN2APLNR | |
| SCHEMBL1421040 | 0.72 | NAMPT (0.48) | CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179045-A1 | LPAR1 ANTAGONISTS AND USES THEREOF | CONTINEUM THERAPEUTICS, INC. | 2025-06-05 | — | — | US | disclosed |
| WO-2023014907-A1 | LPAR1 ANTAGONISTS AND USES THEREOF | Pipeline Therapeutics, Inc. (US) | 2023-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179045-A1 | LPAR1 ANTAGONISTS AND USES THEREOF | LPAR1, LPAR2, LPAR3 | AAK1 892/4885GAA 2146/4885P2RX3 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.